Afinitor (everolimus) vs Exkivity (mobocertinib)

Afinitor (everolimus) is an mTOR inhibitor used to treat various types of cancer, such as advanced renal cell carcinoma, certain breast cancers, and neuroendocrine tumors, among others; its effectiveness depends on the specific genetic markers and characteristics of the cancer. Exkivity (mobocertinib) is a tyrosine kinase inhibitor specifically designed to target and treat non-small cell lung cancer (NSCLC) with a mutation in the EGFR gene, known as exon 20 insertion mutations, and is not used for a broad range of cancers. When deciding between Afinitor and Exkivity, it is crucial to consider the type of cancer, its genetic makeup, and the recommendation of an oncologist, as each medication is tailored for different indications and mechanisms of action.

Difference between Afinitor and Exkivity

Metric	Afinitor (everolimus)	Exkivity (mobocertinib)
Generic name	Everolimus	Mobocertinib
Indications	Advanced hormone receptor-positive, HER2-negative breast cancer, advanced neuroendocrine tumors, renal cell carcinoma, tuberous sclerosis complex	Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations
Mechanism of action	mTOR inhibitor	Tyrosine kinase inhibitor
Brand names	Afinitor, Zortress	Exkivity
Administrative route	Oral	Oral
Side effects	Mouth ulcers, infections, rash, fatigue, diarrhea, edema	Diarrhea, rash, nausea, vomiting, stomatitis
Contraindications	Hypersensitivity to everolimus or other rapamycin derivatives	Hypersensitivity to mobocertinib or any component of the formulation
Drug class	mTOR inhibitor	EGFR inhibitor
Manufacturer	Novartis	Takeda Oncology

Efficacy

Afinitor (Everolimus) Efficacy in Lung Cancer

Afinitor, known by its generic name everolimus, is a medication primarily used to treat various types of cancer and tumors. In the context of lung cancer, everolimus has been studied for its efficacy in treating non-small cell lung cancer (NSCLC), particularly in cases where the cancer is advanced and other treatments have not been effective. Everolimus works by inhibiting the mammalian target of rapamycin (mTOR), a protein that regulates cell growth, proliferation, and survival. By targeting this pathway, Afinitor can slow the growth and spread of cancer cells.

While Afinitor is not primarily indicated for lung cancer, it has been investigated in clinical trials for its potential benefits in NSCLC patients. The results have shown that everolimus can provide a modest improvement in progression-free survival in certain patient populations when used in combination with other treatments, such as chemotherapy or targeted therapies. However, it is important to note that the efficacy can vary based on the individual patient's genetic profile, the stage of cancer, and previous treatments administered.

Exkivity (Mobocertinib) Efficacy in Lung Cancer

Exkivity, with the generic name mobocertinib, is a more recent addition to the arsenal of targeted therapies for lung cancer. It is specifically designed to treat NSCLC that harbors epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These mutations are a group of alterations in the EGFR gene that are implicated in the development and progression of NSCLC. Mobocertinib is an oral tyrosine kinase inhibitor that selectively targets these mutations, thereby inhibiting the growth of cancer cells that express them.

The efficacy of Exkivity in lung cancer has been demonstrated in clinical trials, where it showed significant activity in patients with EGFR exon 20 insertion-positive NSCLC. The trials indicated that mobocertinib could achieve a meaningful objective response rate and had a notable impact on progression-free survival in this patient population. It is important to highlight that Exkivity is specifically approved for patients with this genetic alteration, and its efficacy is closely tied to the presence of EGFR exon 20 insertion mutations. As such, genetic testing is essential before initiating treatment with Exkivity to ensure appropriate patient selection.

Regulatory Agency Approvals

Afinitor

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Exkivity

Food and Drug Administration (FDA), USA

Access Afinitor or Exkivity today

If Afinitor or Exkivity are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Afinitor

Buy Exkivity

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: